Skip to main content
TrimSoMoEverything GLP-1, in one place
← All medications

FDA-approved medication

Foundayo (orforglipron)

Key facts

Last reviewed: 2026-11-06
  • •FDA label says "FOUNDAYO (orforglipron) tablets, for oral use".
  • •FDA label says "Take FOUNDAYO orally once daily, with or without food. ( 2.1 ) Swallow tablets whole. Do not break, crush, or chew. ( 2.1 ) Do not take more than one tablet per day."
  • •FDA label says "FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition."
  • •FDA label says "Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily. ( 2.1 ) After at least 30 days on the 2.5 mg dosage, increase dosage to 5.5 mg once daily. ( 2.1 ) Dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. ( 2.1 ) Maximum dosage is 17.2 mg once daily."

FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.

orforglipron · film-coated tablets (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg) · once daily (with or without food)

Active ingredient
orforglipron
Dosage form (label)
Oral: film-coated tablets (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg)
Schedule (label)
Once daily (with or without food)
Strengths (label)
Tablets: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg of orforglipron. Swallow tablets whole once daily with or without food.Eli Lilly Prescribing Information (USPL) · Lilly Medical Information: Approved Dosing. Accessed November 6, 2026.
Manufacturer
Eli Lilly and Company (per label)

Brand names are trademarks of their respective owners; this site is not affiliated with them.

Illustration of a single round tablet on a circular clay plinth beside a terracotta meal bowl

FDA label

Foundayo dose steps (FDA label)

  1. 0.8 mg
    Days 1–30
    Starting dose (≥ 30 days)
  2. 2.5 mg
    After ≥30 days
    Dose escalation
  3. 5.5 mg
    After ≥30 days
    Dose escalation
  4. 9 mg
    Optional titration
    Based on response & tolerability
  5. 14.5 mg
    Optional titration
    Based on response & tolerability
  6. 17.2 mg
    Label maximum
    maximum dosage
Per FDA label. Your prescriber sets your dose. Take FOUNDAYO orally once daily, with or without food. Swallow tablets whole; do not break, crush, or chew. Starting dosage is 0.8 mg once daily for at least 30 days, then 2.5 mg once daily for at least 30 days, then 5.5 mg once daily for at least 30 days. Dosage may be increased to 9 mg, 14.5 mg, or the maximum dosage of 17.2 mg once daily after at least 30 days on current dosage based on treatment response and tolerability.

FDA label answers

Common questions about Foundayo

All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid 8ac446c5-feba-474f-a103-23facb9b5c62, SPL version 10, revised 08/2026)).

Who is Foundayo approved for?

FDA label says "FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition."

How often is Foundayo taken?

FDA label says "Take FOUNDAYO orally once daily, with or without food. ( 2.1 ) Swallow tablets whole. Do not break, crush, or chew. ( 2.1 ) Do not take more than one tablet per day."

What are the most common side effects listed on the label for Foundayo?

FDA label says "Most common adverse reactions, reported in ≥5% of patients treated with FOUNDAYO, are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss."

Is there a boxed warning on the Foundayo label?

Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents."

What are the dosage strengths and escalation schedule for Foundayo?

FDA label says "Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily. ( 2.1 ) After at least 30 days on the 2.5 mg dosage, increase dosage to 5.5 mg once daily. ( 2.1 ) Dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. ( 2.1 ) Maximum dosage is 17.2 mg once daily."

Patient Consultation & Copay Protocol

Next Steps: Evaluating Foundayo for Your Care Plan

Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.

All Decision Tools
Copay & Savings Card

Out-of-Pocket Expense Modeling

Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.

Covered Commercial: Investigational non-peptide oral agent; commercial terms under development
Uncovered Commercial: Manufacturer assistance models to be announced following Phase 3 ATTAIN readouts
Self-Pay Option: Direct dispensing and retail pharmacy access models under exploration
Medicare: Subject to statutory Medicare Part D anti-obesity medication coverage limitations
Clinical Readiness

Consultation & Lab Checklist

Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.

Required Bloodwork: Liver function monitoring, cardiovascular safety, and glucose indices
Safety Screening: Screening for personal/family history of MTC, MEN 2, pancreatitis, and gallbladder disease.
Clinical Format: Includes 12 essential lab panels and formatted physician questions.
Eligibility & Providers

BMI Qualification & Directory

Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.

FDA Label Threshold: Investigational daily oral candidate; clinical trials target BMI ≥30 or ≥27

Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.

Before Starting Foundayo

Gradual Dose Titration

Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.

Lifestyle & Nutrition Support

In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.

Long-Term Plan

Talk with your clinician before changing or stopping treatment.

Future Pharmacotherapy Outlook

Exploring non-injectable options?

Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.

Oral GLP-1 medicines: see which are FDA-approved and which are still in development →